Sitagliptin: Research, Dosing, and Where to Buy in 2026
A research-first profile for Sitagliptin, aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Sitagliptin is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, 5 attributed expert mentions, and 1 transcript dosing protocol for Sitagliptin, each linked to its source.
- 1 aggregated dosing-protocol mention from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Sitagliptin?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 4 cited mentions
"Cedoptin is being used 100 milligs per day to prevent the breakdown of IGF-1, insulin, TB-500, BPC-157 and potentially KPV and GK copper."
"Dipeptidyl peptidase 4 inhibitors - preventing the breakdown of growth factors. So you raise your erythropoietin levels and your insulin levels and your IGF-1 levels with thymosin alpha 4, thymosin alpha 1."
"How do you manage the risk side effects of a dipeptidyl peptidase 4 inhibitor like Januvia? Uh don't take insulin with it"
Show 1 more cited mention on background and overview →
"Sitagliptin is in there to prevent the breakdown of some of these peptides including IGF-1 and insulin."
Sitagliptin Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve | FULL Quad Tear Recovery Protocol, HGH Serum Tests, Maximize Cardio... | 00:06:03 | Steve reported using 100 mg per day of sitagliptin to inhibit DPP-4 and potentially extend the half-life of injected peptides (TB-500, BPC-157, IGF-1, insulin, possibly KPV/GHK-Cu). | anecdotal |
Where to Buy Sitagliptin in 2026
No tracked vendor recommendations for Sitagliptin yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Sitagliptin. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“Cedoptin is being used 100 milligs per day to prevent the breakdown of IGF-1, insulin, TB-500, BPC-157 and potentially KPV and GK copper.”
See 3 more expert mentions →
-
“Dipeptidyl peptidase 4 inhibitors - preventing the breakdown of growth factors. So you raise your erythropoietin levels and your insulin levels and your IGF-1 levels with thymosin alpha 4,...”
-
“How do you manage the risk side effects of a dipeptidyl peptidase 4 inhibitor like Januvia? Uh don't take insulin with it”
-
“Sitagliptin is in there to prevent the breakdown of some of these peptides including IGF-1 and insulin.”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Sitagliptin. Each line links to the original source.
- "HbA1C decreased significantly from baseline to week 12 in the empagliflozin, sitagliptin, and metformin arm (-1.8, -1.35, -0.69%)." · Mesri Alamdari N et al, 2025 PubMed
- "Compared with the metformin group, the adjusted mean difference in the empagliflozin group was - 12.91 mg/dl (95% CI: 31.82, 6; P = 0.001) for triglyceride (TG) levels and 6.47 mg/dl (95% CI: 2.93, 10.01; P = 0.010) for high-density lipoprotein (HDL-c) levels." · Mesri Alamdari N et al, 2025 PubMed
- "Moreover, empagliflozin led to reductions in SBP about - 8.27 mm Hg (95% CI: -13.31, -3.23; P = 0.001) and in DBP about - 13.37 mm Hg (95% CI: -16.42, -10.32; P = 0.001) compared with metformin." · Mesri Alamdari N et al, 2025 PubMed
- "T2D outpatients aged 65-80 years with moderately controlled glycemic levels (HbA1c 7.4-10.4%) under lifestyle interventions without or with oral anti-diabetic drugs excluding DPP4 inhibitors or GLP-1 receptor agonists were recruited (n = 176)." · Nagao M et al, 2023 PubMed
- "The treatment goal was HbA1c level < 7.4%." · Nagao M et al, 2023 PubMed
Research and Studies
8 PubMed-indexed papers reference Sitagliptin. Top 8 shown.
Legal Status
Sitagliptin is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Sitagliptin FDA-approved?
Sitagliptin is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Sitagliptin?
This page aggregates 1 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Sitagliptin?
8 PubMed-indexed paper(s) reference Sitagliptin in our current research feed. See the Research and Studies section above for citations.